Return to Trial Database

BTCRC-AML17-113

Phase Ib study of the safety and efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: Big Ten Cancer Research Consortium BTCRC-AML17-113

Status

Enrollment Closed

Cancer Type(s)

Study Contact

studies@hoosiercancer.org

Trial Locations

All sites in which the trial BTCRC-AML17-113 being conducted in.

Fred & Pamela Buffett Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

University of Illinois Cancer Center